225 related articles for article (PubMed ID: 32816618)
21. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of pyrrolobenzodiazepine-gallic hybrid agents as p53-dependent and -independent apoptogenic signaling in melanoma cells.
Chou YW; Senadi GC; Chen CY; Kuo KK; Lin YT; Wang JJ; Lee JH; Wang YC; Hu WP
Eur J Med Chem; 2016 Feb; 109():59-74. PubMed ID: 26756315
[TBL] [Abstract][Full Text] [Related]
24. Metastatic malignant melanoma.
Markovic SN; Erickson LA; Flotte TJ; Kottschade LA; McWilliams RR; Jakub JW; Farley DR; Tran NV; Schild SE; Olivier KR; Vuk-Pavlovic S; Sekulic A; Weenig RH; Pulido JS; Quevedo JF; Vile RG; Wiseman GA; Stoian I; Pittelkow MR;
G Ital Dermatol Venereol; 2009 Feb; 144(1):1-26. PubMed ID: 19218908
[TBL] [Abstract][Full Text] [Related]
25. Advances in targeted therapy for melanoma.
Friedlander P; Hodi FS
Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
[TBL] [Abstract][Full Text] [Related]
26. Re-thinking therapeutic development for CNS metastatic disease.
Saberian C; Davies MA
Exp Dermatol; 2022 Jan; 31(1):74-81. PubMed ID: 34152638
[TBL] [Abstract][Full Text] [Related]
27. Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma.
Guttà C; Rahman A; Aura C; Dynoodt P; Charles EM; Hirschenhahn E; Joseph J; Wouters J; de Chaumont C; Rafferty M; Warren M; van den Oord JJ; Gallagher WM; Rehm M
Cell Death Dis; 2020 Feb; 11(2):124. PubMed ID: 32054850
[TBL] [Abstract][Full Text] [Related]
28. New targeted therapies in melanoma.
Kudchadkar RR; Gonzalez R; Lewis K
Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
[TBL] [Abstract][Full Text] [Related]
29. Targeting ferroptosis in melanoma: cancer therapeutics.
Khorsandi K; Esfahani H; Ghamsari SK; Lakhshehei P
Cell Commun Signal; 2023 Nov; 21(1):337. PubMed ID: 37996827
[TBL] [Abstract][Full Text] [Related]
30. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
31. Dioscin induces ferroptosis and synergistic cytotoxicity with chemotherapeutics in melanoma cells.
Xie Y; Chen G
Biochem Biophys Res Commun; 2021 Jun; 557():213-220. PubMed ID: 33878610
[TBL] [Abstract][Full Text] [Related]
32. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
33. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
34. The role of oxidative stress in the biology of melanoma: A systematic review.
Cannavò SP; Tonacci A; Bertino L; Casciaro M; Borgia F; Gangemi S
Pathol Res Pract; 2019 Jan; 215(1):21-28. PubMed ID: 30501931
[TBL] [Abstract][Full Text] [Related]
35. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
Rajakulendran T; Adam DN
Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH analogue.
Rouaud F; Boucher JL; Slama-Schwok A; Rocchi S
Oncotarget; 2016 Dec; 7(50):82804-82819. PubMed ID: 27756874
[TBL] [Abstract][Full Text] [Related]
37. Casticin Induced Apoptosis in A375.S2 Human Melanoma Cells through the Inhibition of NF-[Formula: see text]B and Mitochondria-Dependent Pathways In Vitro and Inhibited Human Melanoma Xenografts in a Mouse Model In Vivo.
Shiue YW; Lu CC; Hsiao YP; Liao CL; Lin JP; Lai KC; Yu CC; Huang YP; Ho HC; Chung JG
Am J Chin Med; 2016; 44(3):637-61. PubMed ID: 27109154
[TBL] [Abstract][Full Text] [Related]
38. New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies.
Ranchon F; Boespflug A; Rioufol C; Schwiertz V; Thomas L; Dalle S
Anticancer Agents Med Chem; 2015; 15(4):461-7. PubMed ID: 25553438
[TBL] [Abstract][Full Text] [Related]
39. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
40. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
